Summary: In healthy adult volunteers (Japanese n=20-21, non-Japanese n=20-21), single-dose cilofexor 100 mg or firsocostat 20 mg showed higher plasma…
Browsing: PICO
Clinical Context Diabetic kidney disease (DKD) remains the leading cause of end-stage renal disease worldwide, affecting approximately 40% of patients…
Clinical Context Prediabetes affects approximately 96 million American adults—more than one-third of the adult population—and represents a critical window for…
Summary: In adults with obesity-related HFpEF (BMI ≥30) from pooled STEP-HFpEF trials (n=1,145), stratified by baseline diuretic use, once-weekly semaglutide…
Summary: In healthy Chinese adults (n=32), once-daily oral semaglutide escalated from 3 mg to 14 mg over 12 weeks demonstrated…
Clinical Context Obesity affects over 650 million adults worldwide and is associated with numerous comorbidities including type 2 diabetes, cardiovascular…
Clinical Context The relationship between obesity and cardiovascular disease has long been recognized, but proving that weight loss reduces cardiovascular…
Summary: In adults with overweight/obesity (BMI ≥27) and established atherosclerotic CVD, without diabetes, semaglutide 2.4 mg once weekly for median…
Summary: In 1,145 patients with obesity-related HFpEF (BMI ≥30, LVEF ≥45%) with NYHA class II-IV symptoms, semaglutide 2.4 mg subcutaneous…
Summary: In adults with type 2 diabetes and CKD (eGFR 25-75, UACR >100-5000 mg/g) on stable ACEi/ARB therapy, semaglutide 1.0…